2-Pyrrolidone → 1-{5-[4-(2,4,5-Trimethylphenyl)piperazine-1-carbonyl]pyridin-2-yl}pyrrolidin-2-one
반응식
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[CH:21]=[C:20]([CH3:22])[C:19]([CH3:23])=[CH:18][C:17]=3[CH3:24])[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[NH:25]1[CH2:29][CH2:28][CH2:27][C:26]1=[O:30]>>[CH3:24][C:17]1[CH:18]=[C:19]([CH3:23])[C:20]([CH3:22])=[CH:21][C:16]=1[N:13]1[CH2:14][CH2:15][N:10]([C:8]([C:5]2[CH:4]=[CH:3][C:2]([N:25]3[CH2:29][CH2:28][CH2:27][C:26]3=[O:30])=[N:7][CH:6]=2)=[O:9])[CH2:11][CH2:12]1참가 물질
3
실험 절차
Using (6-bromopyridin-3-yl)[4-(2,4,5-trimethylphenyl)piperazin-1-yl]methanone (310 mg) described in Preparation Example 173 and pyrrolidin-2-one (93 μL) and by the reaction and treatment in the same manner as in Example 1, the title compound (187 mg) was obtained.
출처 및 근거
- ORD 기록
- ord-9ff2c5aecc6b4e25b28f90e49389bb33
- 출처 데이터셋
- uspto-grants-2014_08